The New England Journal of Medicine retracted a pivotal trial paper for the drug Tavneos following an FDA investigation that revealed unblinded primary endpoint changes.
Mark Hensley, Founder and Managing Director at Hensley Biostats, announced the retraction on LinkedIn. Amgen inherited the medication when it purchased ChemoCentryx for $3.7 billion in 2022.
>>> Manitoba Investigates High School Football Coach Over Hazing Allegations
The regulatory investigation uncovered that the primary endpoint in nine out of 331 patients was readjudicated after the database was locked and unblinded.
This modification was left undisclosed in the published paper.
Biostatistician Mark Hensley highlighted that the week 26 clinical remission results separated the treatment arm from the control by just a few points on a judgment-based scale.
Altering nine reclassified endpoints was enough to shift such a narrow margin after the trial blind was broken.
Hensley noted that the underlying reason for the retraction represents a practice he routinely works to prevent among his own clients.
The regulatory review focused heavily on the timing of the endpoint adjustments relative to the unblinding phase of the clinical study.
Hensley explained that while evaluating borderline cases is standard clinical trial work, conducting it post-unblinding compromises scientific neutrality.
>>> HSR Type 859: A $570,000 Audi Sport Quattro Tribute Based on a Coupe B2
The small number of patients carried significant weight due to the thin statistical margins of the clinical remission scores.
Hensley emphasized that the critical factor distinguishing acceptable trial adjudication from a journal retraction is whether the review happens before or after knowing the patient arms.
He stressed that changing the sequence of events strips the trial of its scientific integrity.
According to Hensley, altering the timeline relative to unblinding invalidates the scientific nature of the process.
He recalled experiencing intense pressure from founders when initial trial results fall just short of statistical targets.
Hensley stated that his professional role under those circumstances is to maintain strict boundaries against breaking the blind.
He concluded by comparing temporary corporate annoyance to the long-term regulatory and reputational costs of a clinical retraction.
>>> Laverne Cox Opens Up About Childhood Trauma and Healing in New Memoir
The consequences of post-unblinding adjustments ultimately jeopardize both the publication and the regulatory standing of the therapeutic product.
